SL010110

CAT: 0804-HY-W197205Size: 1 EachDry Ice: NoHazardous: No

1 / 1

CAT#:0804-HY-W197205Size:1 Each

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

SL010110 is an anti-hyperglycemic agent. SL010110 potently inhibits gluconeogenesis by inhibiting SIRT2, activating p300, and subsequently promoting PEPCK1 degradation. SL010110 downregulates the protein level of PEPCK1 without affecting the gene expressions of PEPCK, glucose-6-phosphatase, and fructose-1,6-bisphosphatase. SL010110 significantly improves glucose homeostasis in type 2 diabetic (T2D) mice model. SL010110 can be used for T2D research[1].

CAS Number

380173-90-0

UNSPSC

12352005

Hazard Statement

H315-H319-H335

Target

Histone Acetyltransferase; PEPCK; Sirtuin

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease

Field of Research

Metabolic Disease

Smiles

C=CCC1=CC(=C(C=C1)OCC2=CC=C(C(=O)O)O2)OC

Molecular Formula

C16H16O5

Molecular Weight

288.30

Precautions

P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362-P403+P233-P405-P501

References & Citations

[1]Ren YR, et al. SL010110, a lead compound, inhibits gluconeogenesis via SIRT2-p300-mediated PEPCK1 degradation and improves glucose homeostasis in diabetic mice. Acta Pharmacol Sin. 2021 Nov;42 (11) :1834-1846.

Shipping Conditions

Room temperature

Scientific Category

Reference compound2

Clinical Information

No Development Reported

Isoform

CBP/p300; SIRT2

SL010110

Popular Products